Tonix Pharmaceuticals Holding Corp.(简称Tonix制药)近日披露了其长效单克隆抗体Tnx-4800的研发计划更新。该抗体药物专为莱姆病的季节性预防而设计,目前已具备进入2/3期临床试验的成熟条件。
Tnx-4800作为一款创新疗法,旨在通过单次注射提供整个莱姆病高发季节的持续保护。此次进展标志着该药物在预防蜱媒传染病领域迈出关键一步。公司表示将基于现有数据与监管机构密切沟通,加快推进临床研究进程。
Tonix Pharmaceuticals Holding Corp.(简称Tonix制药)近日披露了其长效单克隆抗体Tnx-4800的研发计划更新。该抗体药物专为莱姆病的季节性预防而设计,目前已具备进入2/3期临床试验的成熟条件。
Tnx-4800作为一款创新疗法,旨在通过单次注射提供整个莱姆病高发季节的持续保护。此次进展标志着该药物在预防蜱媒传染病领域迈出关键一步。公司表示将基于现有数据与监管机构密切沟通,加快推进临床研究进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.